Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11524 posts found.

celgene_1_02

Celgene boosts cancer portfolio with deal worth up to $2.5 billion with Jounce Therapeutics

July 19, 2016 Research and Development, Sales and Marketing Celgene, jounce

Celgene has entered into a collaboration with Jounce Therapeutics that will see the pair jointly develop and commercialise Jounce’s lead …
News
teva_copy

Teva sells $15 billion in bonds to fund Allergan generics deal

July 19, 2016 Manufacturing and Production, Sales and Marketing Allergan, Teva, bonds, generics

Teva Pharmaceuticals has announced that it has successfully finalised a bond sale totalling $15 billion that will help to fund …
News
novartis_side_building

Novartis lowers core operating profit outlook in Q2 results

July 19, 2016 Manufacturing and Production, Research and Development, Sales and Marketing 2016, Novartis, Q2, results

Novartis has warned that its profits may decline this year as it issued second quarter results, with generic competition for …
News
roche__tree

Roche’s lymphoma drug fails to beat rivals in Phase III trial

July 18, 2016 Research and Development, Sales and Marketing Roche, lymphoma, phase III

Roche has announced that a Phase III trial evaluating Gazyva/Gazyvaro (obinutuzumab) in patients with previously untreated diffuse large B-cell lymphoma …
News
samsung

Samsung Bioepis Humira biosimilar gets accepted for EMA review

July 18, 2016 Research and Development, Sales and Marketing EMA, Humira, Samsung Bioepis, application

The European Medicines Agency (EMA) has accepted for review the marketing authorisation application from Samsung Bioepis for their biosimilar version …
News

FDA approves first extended depth of focus lenses for people with cataracts

July 18, 2016 Research and Development, Sales and Marketing Abbott, FDA, cataracts

Abbott has announced that the Tecnis Symfony Intraocular Lenses for the treatment of cataracts has been approved by the US …
News
fda_sign_web

Valeant’s psoriasis drug “difficult to assess”, according to FDA staff

July 18, 2016 Research and Development, Sales and Marketing FDA, Valeant, psoriasis

Staff at the US Food and Drug Administration have expressed concerns over Valeant’s psoriasis candidate, brodalumab, due to the potential …
News
clinical_trial_4

Patient death in gene therapy trial sends Ziopharm stocks falling

July 18, 2016 Research and Development, Sales and Marketing ziopharm

Ziopharm Oncology has issued a statement following the death of a patient enrolled on a Phase I clinical trial for …
News
msd

UK medical charity sells part of interest in MSD’s Keytruda for $150 million

July 15, 2016 Research and Development, Sales and Marketing MSD, Merck, keytruda

UK medical research charity MRC Technology sold part of its royalty interest in US pharma major MSD’s (NYSE: MRK) immunotherapy …
News
stocks1

Weekly Movers: CytRx, Coherus BioSciences, Juno Therapeutics…

July 15, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Coherus BioSciences, GW Pharmaceuticals, Sage Therapeutics, Share price, Shares, Stock Markets, cytrx, juno therapeutics

Shares in CytRx (Nasdaq: CYTR) lost nearly three-fourth in value after the company reported disappointing late-stage results for its lead …
Feature

Bayer adds extra $2 billion to Monsanto bid

July 15, 2016 Medical Communications, Sales and Marketing Bayer, monsanto

German pharma company Bayer (ETR: BAYN) have upped their bid for Monsanto (NYSE: MON) to $64 billion, putting pressure on …
News

Busy week at Juno Therapeutics ends with takeover of RedoxTherapies

July 15, 2016 Medical Communications, Research and Development, Sales and Marketing juno therapeutics, redoxtherapies, takeover, vipadenant

Juno Therapeutics (NASDAQ: JUNO) has announced the acquisition of RedoxTherapies, adding its lead cancer drug candidate, vipadenant, to its portfolio.
News
teva_copy

Teva looking at up to $25 billion in bond sale to fund Allergan’s generic-unit buy – reports

July 15, 2016 Medical Communications, Sales and Marketing Allergan, Financial, Teva, US regulators, bond sale, deal

Israeli drug firm Teva (NYSE: TEVA) is looking at a $20 billion to $25 billion bond sale in the US …
News
celgene_1_02

Celgene says its Revlimid gets European approval to treat rare non-Hodgkin’s lymphoma

July 15, 2016 Medical Communications, Research and Development, Sales and Marketing Celgene, European Commission, Revlimid, drug approval, drug trial, oncology

Celgene (Nasdaq: CELG) said the European Commission (EC) has approved Revlimid (lenalidomide) to treat a rare form of non-Hodgkin’s lymphoma. 
News
cancerstudy

Lilly, Boehringer Ingelheim to jointly study combination therapy for breast cancer

July 14, 2016 Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, breast cancer, combination therapy, drug trial

US drug major Eli Lilly (NYSE: LLY) and Boehringer Ingelheim said they will jointly initiate early combination trials in breast cancer. The …
News
The Gateway to Local Adoption Series

Latest content

Thermo Fisher opens new distribution centre in Ireland

March 12, 2026

Altimetrik appoints Dhirendra Nath as Chief Human Resources Officer

March 12, 2026

Kindeva appoints Mike Cowhig as Chief Legal Officer

March 11, 2026

DiaMedica gets regulatory clearance from Health Canada for phase 2 preeclampsia study

March 11, 2026

Abselion establishes a US subsidiary in Massachusetts 

March 10, 2026